Drug
Ataluren
Ataluren: highest development phase Phase 3, developed by PTC Therapeutics. 14 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- PTC Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ataluren NCT00803205 | Phase 3 | Cystic Fibrosis |
| Ataluren (PTC124®) NCT02139306 | Phase 3 | Cystic Fibrosis |
| Ataluren NCT01140451 | Phase 3 | Cystic Fibrosis |
| Ataluren NCT03179631 | Phase 3 | Muscular Dystrophy, Duchenne |
| Ataluren NCT01247207 | Phase 3 | Duchenne Muscular Dystrophy |
| Ataluren NCT02107859 | Phase 3 | Cystic Fibrosis |
| Ataluren NCT02090959 | Phase 3 | Muscular Dystrophy, Duchenne |
| ataluren NCT02758626 | Phase 2 | Epilepsy |
| Ataluren NCT00847379 | Phase 2 | Duchenne Muscular Dystrophy |
| Ataluren NCT01009294 | Phase 2 | Duchenne Muscular Dystrophy |
| Ataluren NCT00759876 | Phase 2 | Duchenne Muscular Dystrophy |
| Ataluren NCT04336826 | Phase 2 | Nonsene Mutation Duchenne Muscular Dystrophy |
| Ataluren NCT01141075 | Phase 2 | Amino Acid Metabolism, Inborn Errors |
| Ataluren NCT02409004 | Phase 1 | Healthy |
Latest
No recent events.
Follow Ataluren on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.